Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma by Min Meng, Yi-chen Wu

“…Chimeric antigen receptor-modified T cell (CAR-T) therapy has great potential for treating malignant tumors, especially hematological malignancies. However, the therapeutic effect of solid tumors is limited. …”
Get full text

iPSC Technology Revolutionizes CAR-T Cell Therapy for Cancer Treatment by Jiepu Zong, Yan-Ruide Li

“…CAR-T cell therapy has demonstrated notable efficacy in the treatment of hematological malignancies, solid tumors, and various infectious diseases. …”
Get full text

Loading of CAR‐T cells with magnetic nanoparticles for controlled targeting suppresses inflammatory cytokine release and switches tumor cell death mechanism by Felix Pfister, Lucas R. Carnell, Lisa Löffler, Philipp Boosz, Niels Schaft, Jan Dörrie, René Stein, Malte Lenz, Erdmann Spiecker, Christian M. Huber, Sami Haddadin, Carola Berking, Christoph Alexiou, Christina Janko

“…Abstract Therapies against hematological malignancies using chimeric antigen receptors (CAR)‐T cells have shown great potential; however, therapeutic success in solid tumors has been constrained due to limited tumor trafficking and infiltration, as well as the scarcity of cancer‐specific solid tumor antigens. …”
Get full text

Case report: Dysphonia associated with high-dose cytarabine therapy by Ling Ma, Niya Huang, Haixi Zhang, Jia Liu, Zhiqing Zhang

“…Cytarabine is widely used in the treatment of hematological malignancies. Its common toxicities include myelosuppression and gastrointestinal disturbances. …”
Get full text

CD4+CD25highCD127low/-FoxP3+ Regulatory T-Cell Population in Acute Leukemias: A Review of the Literature by M. Niedźwiecki, O. Budziło, E. Adamkiewicz-Drożyńska, D. Pawlik-Gwozdecka, M. Zieliński, L. Maciejka-Kembłowska, T. Szczepański, P. Trzonkowski

“…However, observations confirming these facts are scarce; thus, extrapolating them to the population of children with hematological malignancies needs to be verified in additional studies.…”
Get full text

An Unusually Short Latent Period of Therapy-Related Myeloid Neoplasm Harboring a Rare MLL-EP300 Rearrangement: Case Report and Literature Review by Reina Takeda, Kazuaki Yokoyama, Seiichiro Kobayashi, Toyotaka Kawamata, Sousuke Nakamura, Tomofusa Fukuyama, Mika Ito, Nozomi Yusa, Eigo Shimizu, Nobuhiro Ohno, Rui Yamaguchi, Seiya Imoto, Satoru Miyano, Kaoru Uchimaru, Arinobu Tojo

“…Therapy-related myeloid neoplasm (t-MN) is a late and lethal complication induced by chemotherapy and/or radiation therapy. Hematological malignancy is one of the most common primary diseases in patients with t-MN. …”
Get full text

Detection of early relapse in multiple myeloma patients by Tereza Růžičková, Monika Vlachová, Lukáš Pečinka, Monika Brychtová, Marek Večeřa, Lenka Radová, Simona Ševčíková, Marie Jarošová, Josef Havel, Luděk Pour, Sabina Ševčíková

“…Abstract Background Multiple myeloma (MM) represents the second most common hematological malignancy characterized by the infiltration of the bone marrow by plasma cells that produce monoclonal immunoglobulin. …”
Get full text

Systematic Characterization of Splicing Dysregulation in Pan Solid Tumor Transcriptome by Jingru Sui, Dan Guo, Xiao Wen, Lei Zhou, Yue Huang, Haoyu Yu, Jinyu Chen, Zhaoqi Liu

“…Abstract Splicing dysregulation arising from spliceosomal mutations contributes to disease progression and treatment resistance, mostly in hematologic malignancy. Whereas spliceosomal mutations are less common in solid tumors, splicing disorders are pervasive and proven to promote tumorigenesis. …”
Get full text

Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma by Ka-Won Kang, Dae Sik Kim, Se Ryeon Lee, Mi Hwa Heo, Hyeon-Seok Eom, Jongheon Jung, Ji Hyun Lee, Sung-Hyun Kim, Youngil Koh, Chang-Ki Min, Seung Shin Lee, Sung-Nam Lim, Ho-Young Yhim, Myung-won Lee, Je-Jung Lee, Sung-Hoon Jung, Soo-Mee Bang, Kihyun Kim, the Korean Multiple Myeloma Working party [KMMWP]

Get full text

The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen by Quane Zhang, Yifan Wang, Wenting Shi, Yue Chen, Zhengmei He, Liang Yu, Chunling Wang

“…Abstract Multiple myeloma (MM) is the second most common hematological malignancy. Previous studies have validated the prognostic significance of the platelet-to-lymphocyte ratio (PLR) in patients with certain solid tumors. …”
Get full text

Concordance of Peripheral Blood and Bone Marrow Next-Generation Sequencing in Hematologic Neoplasms by Chayanit Jumniensuk, Alexander Nobori, Thomas Lee, T. Niroshi Senaratne, Dinesh Rao, Sheeja Pullarkat

“…We evaluated patients who had NGS for presumed hematologic malignancy performed on peripheral blood and bone marrow within a 1-year interval of each other. …”
Get full text

Presentation of disseminated neuroblastoma mimicking Bell’s palsy: a case report by Shamaali Gunawardana, Geerthana Jogaprajahpan, Kavinda Dayasiri

“…Conclusion Facial nerve palsy is well recognized to have a myriad of underlying etiologies, including hematological malignancies, solid tumors, and paraneoplastic syndromes. …”
Get full text

Pooled screening for CAR function identifies novel IL-13Rα2-targeted CARs for treatment of glioblastoma by Douglas A Lauffenburger, Khloe S Gordon, Caleb R Perez, Andrea Garmilla, Maxine S Y Lam, Joey J Y Aw, Anisha Datta, Andrea Pavesi, Michael E Birnbaum

“…It also showed significantly improved persistence and comparable tumor control in a microphysiological human in vitro model and a xenograft model of human glioblastoma, but also demonstrated increased off-target recognition of IL-13Rα1.Conclusion Taken together, this work demonstrates the utility of extending CARPOOL to diseases beyond hematological malignancies and represents the largest exploration of signaling combinations in human primary cells to date.…”
Get full text

Primary Bone Marrow B-Cell Lymphoma Undetected by Multiple Imaging Modalities That Initially Presented with Hypercalcemia by Jin Sae Yoo, Juwon Kim, Hyeong Ju Kwon, Jung Soo Lim

“…A bone marrow biopsy was performed to identify any hidden hematologic malignancy. As a result, the pathology of bone marrow confirmed the presence of atypical lymphocytes that stained positive for the CD20 marker, which is consistent with BCL involving the bone marrow. …”
Get full text

ANTIBIOTIC LOCK THERAPY FOR PORT CATHETER-RELATED INFECTIONS OF CHILDREN WITH ACUTE LEUKEMIA by Burçin Kurtipek, Ayça Koca Yozgat, Saliha Kanık Yüksek, Dilek Kaçar, Turan Bayhan, Dilek Gürlek Gökçebay, Aslınur Özkaya Parlak, Neşe Yaralı

“… Background: Port catheters facilitate the administration of chemotherapy, antibiotics, blood products, fluid and parenteral nutritional support to pediatric patients with hematological malignancies. However, as its use has become widespread, local, and systemic catheter-related infections have emerged as important causes of morbidity and mortality. …”
Get full text

Graft-Versus-Host Disease Sustains Coagulation Activity for two Years After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation by Satu Långström MD, PhD, Minna Koskenvuo MD, PhD, Pasi Huttunen MD, PhD, Riitta Lassila MD, PhD, Mervi Taskinen MD, PhD, Susanna Ranta MD, PhD, Markku Heikinheimo MD, PhD, Anne Mäkipernaa MD, PhD

“…Aim To evaluate the longitudinal coagulation profile after allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with hematological malignancies. Methods Several coagulation variables were measured at predetermined time points for two years after HSCT in 30 pediatric patients. …”
Get full text

Impact of leukemia subtype and demographics on patient quality of life in 76 countries: a cross-sectional study by Sam Salek, Samantha Nier, Zack Pemberton-Whiteley, Tatyana Ionova, Giuseppe Ianni, Giovanni Tripepi, Nick York, Nicole Schroeter, Kathryn Huntley, Michael Rynne, Denis Costello, Lidija Pecova, Esther Natalie Oliva

“…BackgroundDisease-specific factors associated with decreased quality of life (QoL) in patients with leukemia have not been studied in a large-scale, global, observational study.MethodsThis cross-sectional study used the validated Hematological Malignancy Patient Reported Outcomes (HM-PRO) questionnaire to assess the impact of leukemia subtype, age, sex, and years living with the disease on QoL of patients with leukemia.ResultsOverall, 2,628 patients responded: 45.7% had chronic lymphocytic leukemia (CLL), 34.0% had chronic myeloid leukemia (CML), 11.8% had acute myeloid leukemia (AML), and 3.5% had acute lymphoblastic leukemia (ALL). …”
Get full text

Survival in patients with acute non-lymphoblastic leukemia at the "Dr. Gustavo Aldereguía Lima". Hospital. A ten years experience by Rafael Alejandro Gómez Baute, Julio Dámaso Fernández Águila., Liermis Dita Salabert, Tamara Guerra Alfonso

“…Data were obtained from the record book of hematological malignancies from the Oncohematology Department. …”
Get full text

Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment by Robert Brown, Marco Donia, Simon Turcotte, George Coukos, John Mullinax, Brian Gastman, James C Yang, Michael T Lotze, John B A G Haanen, Inge Marie Svane, Stephanie L Goff, Vernon K Sondak, Maartje W Rohaan, Michal Besser, Benjamin Creelan

“…Since the advent of chimeric antigen receptor (CAR) T cells for patients with hematological malignancies, a growing network of centers capable of delivering effector T cell products to patients has developed. …”
Get full text

Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study—The Tumor Anemia Registry by Tilman Steinmetz, Jan Schröder, Margarete Plath, Hartmut Link, Michèle Vogt, Melanie Frank, Norbert Marschner

“…Patients were followed up for 12 weeks. 63% of the patients had inoperable solid tumors, 22% operable solid tumors, and 15% hematological malignancies. Over 85% received chemotherapy. …”
Get full text